Revenue from Contracts with Customers

Disaggregated Revenues

The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands):



	Year Ended December 31, 2019
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	18,578	$	8,083	$	4,413	$	31,074
Consumables	35,461		12,484		3,646		51,591
In vitro diagnostic kits	2,522		6,601		290		9,413
Total product revenue	56,561		27,168		8,349		92,078
Service revenue	7,724		3,121		791		11,636
Total product and service revenue	64,285		30,289		9,140		103,714
Collaboration revenue	21,854		—		—		21,854
Total revenues	$	86,139	$	30,289	$	9,140	$	125,568



	Year Ended December 31, 2018
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	12,033	$	6,677	$	2,731	$	21,441
Consumables	29,653		10,847		3,347		43,847
In vitro diagnostic kits	3,014		6,094		337		9,445
Total product revenue	44,700		23,618		6,415		74,733
Service revenue	6,228		2,097		465		8,790
Total product and service revenue	50,928		25,715		6,880		83,523
Collaboration revenue	23,209		—		—		23,209
Total revenues	$	74,137	$	25,715	$	6,880	$	106,732



	Year Ended December 31, 2017⁽¹⁾
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	10,556	$	6,561	$	3,722	$	20,839
Consumables	25,583		9,934		2,794		38,311
In vitro diagnostic kits	2,473		3,982		290		6,745
Total product revenue	38,612		20,477		6,806		65,895
Service revenue	4,592		1,314		209		6,115
Total product and service revenue	43,204		21,791		7,015		72,010
Collaboration revenue	42,895		—		—		42,895
Total revenues	$	86,099	$	21,791	$	7,015	$	114,905

⁽¹⁾ Amounts have not been retrospectively modified to reflect the adoption of Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers, for the year ended December 31, 2017.

Contract balances and remaining performance obligations

Contract liabilities are comprised of the current and long-term portions of deferred revenue of $5.0 million and $11.5 million as of December 31, 2019 and December 31, 2018, respectively, and customer deposits of $6.4 million and $8.2 million as of December 31, 2019 and December 31, 2018, respectively, included within the consolidated balance sheets. Total contract liabilities decreased by $8.3 million for the year ended December 31, 2019 as a result of the recognition of previously deferred revenue and customer deposits of $29.4 million for the completion of certain performance obligations during the period, partially offset by cash payments received of $21.1 million related to our collaborations and service contracts. The Company did not record any contract assets as of December 31, 2019. The Company’s contractual payment terms for its contracts with customers are typically no more than 30 days.

As of December 31, 2019, unsatisfied or partially unsatisfied performance obligations related to the collaboration agreement with Lam Research Corporation (“Lam”) were $5.5 million and are expected to be completed by the first half of 2020. Performance obligations related to undelivered products and service contracts as of December 31, 2019 were $5.7 million and are expected to be completed over the term of the related contract, or as products are delivered.